» Articles » PMID: 37100941

Computational Approaches Streamlining Drug Discovery

Overview
Journal Nature
Specialty Science
Date 2023 Apr 26
PMID 37100941
Authors
Affiliations
Soon will be listed here.
Abstract

Computer-aided drug discovery has been around for decades, although the past few years have seen a tectonic shift towards embracing computational technologies in both academia and pharma. This shift is largely defined by the flood of data on ligand properties and binding to therapeutic targets and their 3D structures, abundant computing capacities and the advent of on-demand virtual libraries of drug-like small molecules in their billions. Taking full advantage of these resources requires fast computational methods for effective ligand screening. This includes structure-based virtual screening of gigascale chemical spaces, further facilitated by fast iterative screening approaches. Highly synergistic are developments in deep learning predictions of ligand properties and target activities in lieu of receptor structure. Here we review recent advances in ligand discovery technologies, their potential for reshaping the whole process of drug discovery and development, as well as the challenges they encounter. We also discuss how the rapid identification of highly diverse, potent, target-selective and drug-like ligands to protein targets can democratize the drug discovery process, presenting new opportunities for the cost-effective development of safer and more effective small-molecule treatments.

Citing Articles

Identification of (L.) Merr as a Novel Potential Therapeutic Agent Against COVID-19 and Pharyngitis.

Chen Q, He H, Zhu Y, Li X, Fang J, Li Z Molecules. 2025; 30(5).

PMID: 40076279 PMC: 11901475. DOI: 10.3390/molecules30051055.


A structure-based framework for selective inhibitor design and optimization.

Zou Y, Guo T, Fu Z, Guo Z, Bo W, Yan D Commun Biol. 2025; 8(1):422.

PMID: 40075154 PMC: 11903766. DOI: 10.1038/s42003-025-07840-3.


DockEM: an enhanced method for atomic-scale protein-ligand docking refinement leveraging low-to-medium resolution cryo-EM density maps.

Zou J, Zhang W, Hu J, Zhou X, Zhang B Brief Bioinform. 2025; 26(2).

PMID: 40062618 PMC: 11891657. DOI: 10.1093/bib/bbaf091.


Structural bioinformatics for rational drug design.

Mozaffari S, Moen A, Ng C, Nicolaes G, Wichapong K Res Pract Thromb Haemost. 2025; 9(1):102691.

PMID: 40027444 PMC: 11869865. DOI: 10.1016/j.rpth.2025.102691.


High throughput screening identifies potential inhibitors targeting trimethoprim resistant DfrA1 protein in Klebsiella pneumoniae and Escherichia coli.

Hasnat S, Rahman S, Alam M, Suin F, Yeasmin F, Suha T Sci Rep. 2025; 15(1):7141.

PMID: 40021806 PMC: 11871338. DOI: 10.1038/s41598-025-91410-4.


References
1.
Sun D, Gao W, Hu H, Zhou S . Why 90% of clinical drug development fails and how to improve it?. Acta Pharm Sin B. 2022; 12(7):3049-3062. PMC: 9293739. DOI: 10.1016/j.apsb.2022.02.002. View

2.
Van Drie J . Computer-aided drug design: the next 20 years. J Comput Aided Mol Des. 2007; 21(10-11):591-601. DOI: 10.1007/s10822-007-9142-y. View

3.
Talele T, Khedkar S, Rigby A . Successful applications of computer aided drug discovery: moving drugs from concept to the clinic. Curr Top Med Chem. 2009; 10(1):127-41. DOI: 10.2174/156802610790232251. View

4.
Sabe V, Ntombela T, Jhamba L, Maguire G, Govender T, Naicker T . Current trends in computer aided drug design and a highlight of drugs discovered via computational techniques: A review. Eur J Med Chem. 2021; 224:113705. DOI: 10.1016/j.ejmech.2021.113705. View

5.
Jayatunga M, Xie W, Ruder L, Schulze U, Meier C . AI in small-molecule drug discovery: a coming wave?. Nat Rev Drug Discov. 2022; 21(3):175-176. DOI: 10.1038/d41573-022-00025-1. View